My concerns are mainly SVFC goals and timelines.
The addition of Mr. Hill means to me that a strategic decision will be reached by the BOD about continuing as a public shareholding company or taking the company private. He has the particular experience and skill set to inform that decision. IMO that will not take years, but rather months. Look at Hill's history with large firms.
How long current shareholders have to benefit from the technology this company seeks to develop may suddenly change. If it becomes evident that billions are at stake, Hill's efforts may attract deep pocket investors rather quickly. Removing the current risks of toxic financing is vital to this firm moving forward, whether the decision is to keep the company public or take it private.
I'm thinking out loud about what I see is possible due to the addition of Mr. Hill to the BOD. I have no inside information about why him at this time. But the BOD made the decision, and he agreed, for good reasons.
I'm concerned because I would prefer a LT investment in SVFC to become very profitable for me. But I've seen a number of biotechs that had a MC well above the one at the time of the buyout or partnership. Remember the old saying: "Don't count your chickens . . . ."
